340B Hospitals Playing 'Outsize' Medicare Role In Many Therapeutic Categories
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysis supported by drug industry adds to growing research on scale of Medicare Part B payments to hospitals receiving 340B drug discounts.
You may also be interested in...
340B Needs Legislative Fix For Overspending On Medicare Patients, GAO Says
Drug discount program creates financial incentive for participating hospitals to prescribe more drugs or more expensive drugs reimbursed by Medicare Part B, resulting in 'substantially higher' spending, a GAO report says.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.